Introducing the BenevolentAI and UCL PhDs

Inviting students to train as the experts of tomorrow in applying machine learning to human genetics and electronic health records. The UCL Centre for Translational Genomics (CTG) and Institute for Health Informatics (IHI) are international centres of excellence for research in these two areas and we are excited about further strengthening our already established links with them both.

Read More
New Strategic Partnership with AstraZeneca

Today we announced a major milestone in the shape of a long-term strategic collaboration with AstraZeneca. This partnership combines BenevolentAI’s expertise in AI and machine learning to identify novel insights from scientific data with AstraZeneca’s excellence in R&D to identify new targets in two therapeutic areas of huge unmet need: Idiopathic Pulmonary Fibrosis (IPF) and Chronic Kidney Disease (CKD).

Read More
Using Artificial Intelligence to Optimise Small-Molecule Drug Design

Here at BenevolentAI, we are unlocking the power of scientific data so no disease goes untreated. We achieve this in a variety of ways, right from initial target identification and validation, through hit discovery and lead optimisation, and finally into the clinic, making us the only end-to-end drug discovery company driven by Artificial Intelligence (AI) in the world.

Read More